123 related articles for article (PubMed ID: 21416694)
1. Pyrazinamide plasma concentrations in young children with tuberculosis.
McIlleron H; Willemse M; Schaaf HS; Smith PJ; Donald PR
Pediatr Infect Dis J; 2011 Mar; 30(3):262-5. PubMed ID: 21416694
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
[TBL] [Abstract][Full Text] [Related]
3. Blood levels of pyrazinamide in children at doses administered under the Revised National Tuberculosis Control Program.
Roy V; Sahni P; Gupta P; Sethi GR; Khanna A
Indian Pediatr; 2012 Sep; 49(9):721-5. PubMed ID: 22317983
[TBL] [Abstract][Full Text] [Related]
4. Pyrazinamide serum levels in childhood tuberculosis.
Thee S; Detjen A; Wahn U; Magdorf K
Int J Tuberc Lung Dis; 2008 Sep; 12(9):1099-101. PubMed ID: 18713511
[TBL] [Abstract][Full Text] [Related]
5. Pyrazinamide blood concentrations in children suffering from tuberculosis: a comparative study at two doses.
Gupta P; Roy V; Sethi GR; Mishra TK
Br J Clin Pharmacol; 2008 Mar; 65(3):423-7. PubMed ID: 18093254
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
Verhagen LM; López D; Hermans PW; Warris A; de Groot R; García JF; de Waard JH; Aarnoutse RE
Trop Med Int Health; 2012 Dec; 17(12):1449-56. PubMed ID: 23094704
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status.
Dayal R; Singh Y; Agarwal D; Kumar M; Swaminathan S; Ramachandran G; Kumar S; Narayan S; Goyal A; Kumar AKH
Arch Dis Child; 2018 Dec; 103(12):1150-1154. PubMed ID: 29514812
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis.
Zhu M; Starke JR; Burman WJ; Steiner P; Stambaugh JJ; Ashkin D; Bulpitt AE; Berning SE; Peloquin CA
Pharmacotherapy; 2002 Jun; 22(6):686-95. PubMed ID: 12066959
[TBL] [Abstract][Full Text] [Related]
9. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
[TBL] [Abstract][Full Text] [Related]
10. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
Ramachandran G; Kumar AK; Kannan T; Bhavani PK; Kumar SR; Gangadevi NP; Banurekha VV; Sudha V; Venkatesh S; Ravichandran N; Kalpana S; Mathevan G; Sanjeeva GN; Agarwal D; Swaminathan S
Pediatr Infect Dis J; 2016 May; 35(5):530-4. PubMed ID: 26825153
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment.
Stemkens R; Litjens CHC; Dian S; Ganiem AR; Yunivita V; van Crevel R; Te Brake LHM; Ruslami R; Aarnoutse RE
Int J Antimicrob Agents; 2019 Sep; 54(3):371-374. PubMed ID: 31202922
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.
Martial LC; Kerkhoff J; Martinez N; Rodríguez M; Coronel R; Molinas G; Roman M; Gomez R; Aguirre S; Jongedijk E; Huisman J; Touw DJ; Pérez D; Chaparro G; Gonzalez F; Aarnoutse RE; Alffenaar JW; Magis-Escurra C
Int J Antimicrob Agents; 2018 Jul; 52(1):109-113. PubMed ID: 29751121
[TBL] [Abstract][Full Text] [Related]
13. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
Kumar AK; Chandrasekaran V; Kannan T; Murali AL; Lavanya J; Sudha V; Swaminathan S; Ramachandran G
Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
[TBL] [Abstract][Full Text] [Related]
14. A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies.
Srivastava S; Pasipanodya JG; Ramachandran G; Deshpande D; Shuford S; Crosswell HE; Cirrincione KN; Sherman CM; Swaminathan S; Gumbo T
EBioMedicine; 2016 Apr; 6():126-138. PubMed ID: 27211555
[TBL] [Abstract][Full Text] [Related]
15. Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs.
Kumar AKH; Chandrasekaran V; Kumar AK; Kawaskar M; Lavanya J; Swaminathan S; Ramachandran G
Indian J Med Res; 2017 Apr; 145(4):530-535. PubMed ID: 28862186
[TBL] [Abstract][Full Text] [Related]
16. Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.
McIlleron H; Willemse M; Werely CJ; Hussey GD; Schaaf HS; Smith PJ; Donald PR
Clin Infect Dis; 2009 Jun; 48(11):1547-53. PubMed ID: 19392636
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of anti-TB drugs in Malawian children: reconsidering the role of ethambutol.
Mlotha R; Waterhouse D; Dzinjalamala F; Ardrey A; Molyneux E; Davies GR; Ward S
J Antimicrob Chemother; 2015; 70(6):1798-803. PubMed ID: 25759035
[TBL] [Abstract][Full Text] [Related]
18. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of Rifampicin and Pyrazinamide with pre and post meal administration in tuberculosis patients.
Sharma PK; Bansal R; Bhardwaj AK; Sood V; Sood A; Padwad Y
Indian J Tuberc; 2018 Jan; 65(1):35-40. PubMed ID: 29332645
[TBL] [Abstract][Full Text] [Related]
20. Quantification of pyrazinamide and its metabolites in plasma by ionic-pair high-performance liquid chromatography. Implications for the separation mechanism.
Kraemer HJ; Feltkamp U; Breithaupt H
J Chromatogr B Biomed Sci Appl; 1998 Mar; 706(2):319-28. PubMed ID: 9551819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
